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Inherited	 bleeding,	 thrombotic,	 and	 platelet	 disorders	 (BTPD)	 are	 a	
heterogeneous	 set	of	diseases.	The	most	 common	 inherited	bleed-




boring	 variants	 responsible	 for	BTPD	have	been	 identified	 through	
linkage	 studies	 across	 informative	 pedigrees	 or	 using	 candidate	




developed	 using	 targeted	 or	 exome	 sequencing.1,3–9	 Interestingly,	
when	comparing	 the	gene	 content	of	 these	different	 genetic	panel	
tests,	 significant	 differences	were	 observed.	 A	 first	 level	 of	 differ-
ence	was	created	by	the	choice	of	genes	tested	for	BTPD.	These	in-
cluded	established	genes,	known	for	decades	to	play	a	role	in	many	
families	with	BTPD	(e.g.,	F8, F9, VWF, PROS1, PROC, ITGA2B, ITGB3,	
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amongst	many	others),	genes	with	limited	evidence	from	publications	
of	single	pedigrees,	and,	 finally,	genes	 identified	 through	 functional	
studies	 and/or	knockout	mice	but	without	 a	 known	defined	 role	 in	
human	pathology.	The	first	group	of	genes	are	the	diagnostic-	grade	




as	 those	 for	 hereditary	 hemorrhagic	 telangiectasia	 (ENG, SMAD4, 
ACVRL11),	Ehlers	Danlos	syndrome	(e.g.,	COL1A1, COL3A1, COL5A1, 
COL5A2, CHST14),	 Gaucher	 syndrome	 (GBA),	 or	 Noonan	 syndrome	
(e.g.,	PTPN11).	 These	 genes	 are	 TIER1	 genes	 for	 disorders	 that	 are	
often	 associated	 with	 primary	 phenotypes	 such	 as	 arteriovenous	





























2  | DESCRIPTION OF THE GENE AND 
TR ANSCRIPT CUR ATION PROCESS
2.1 | Historical background and gene curation process
We	have	assembled	a	list	of	91	TIER1	genes	that	are	germline	mutated	









to	 coagulation	 deficiencies	 implicated	 in	 bleeding,	 9	 genes	 known	
to	be	associated	with	 thrombosis,	and	61	genes	 involved	 in	defects	









TIER1	 genes	 that	 cause	 disease.	Most	BTPDs	 are	 caused	by	 inacti-
vating	missense	or	loss-	of-	function	(LoF)	variants	that	are	distributed	
throughout	 the	gene,	whereas	others	 are	exclusively	 caused	by	LoF	
variants	 (e.g.,	PIGA, BLOC1S3, BLOC1S6, DTNBP1, FYB1).	 In	contrast,	
some	BTPDs	are	the	result	of	activating	missense	or	LoF	variants	that	
mostly	 occur	 in	 specific	 protein	 domains	 (e.g.,	 THBD, DIAPH1, SRC, 





in	Table	S1,	and	multiple	modes	of	inheritance	(e.g.,	VWF, FLI1, GFI1B, 
PROC)	are	encoded	within	the	“Inheritance”	column.
To	 curate	each	gene-	disease	pair,	 three	 layers	of	 evidence	were	
collated	that	provide	support	for	disease	association,	mode	of	inher-
itance	 and	 disease-	causing	 “mutational	 mechanism.”	 The	 first	 level	


















as	 the	 associated	 human	 disease.	 This	 information	was	 taken	 from	
the	Mouse	 Genome	 Informatics	 (www.infor	matics.jax.org)	 database	
or	 a	 PubMed	 reference	 (“Level	 3	 evidence”	 in	Table	 S1).	 Twenty	 of	
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the	genes	had	a	mouse	model	that	did	not	mimic	the	human	disease,	
whereas	for	five	genes,	no	model	has	been	developed.
In	 summary,	 evidence-	based	 curation	 resulted	 in	 a	 total	 of	 91	
genes	 that	 reached	 a	 TIER1	 status	 (Table	 1).	 These	 were	 gene-	
disease	association	identified	in	at	 least	three	genetically	 indepen-
dent	 families	 with	 supportive	 genotype-	phenotype	 cosegregation	
data	or	with	robust	support	from	functional	studies	and/or	a	mouse	
phenocopy	 matching	 the	 human	 disease	 where	 less	 than	 three	
families	 are	 known	 in	 combination	 with	 linkage	 analysis	 data	 for	
large	pedigrees.	The	list	 is	versioned	and	will	be	reassessed	by	the	





gene,	 the	 curated	 transcript	was	 selected,	 in	 collaboration	with	 the	
Locus	 Reference	 Genomic	 project	 (LRG;	 http://www.lrg-	sequence.
org/),12	 based	 on	 recommendations	 by	members	 of	 the	 SSC-	GinTH	
community,	 previously	 reported	 causal	 variants	 in	 Human	 Gene	
Mutation	Database	 and	ClinVar,	 transcript	 and	 protein	 lengths,	 and	
considering	 RNA-	sequencing	 expression	 data	 in	 blood	 cells,	 other	
relevant	 tissues,	 and	 cap	 analysis	 gene	 expression	data	 for	 defining	
the	most	common	transcription	start	site	(Table	1	and	Table	S1).	For	
some	genes,	more	than	one	transcript	was	included	in	the	LRG	record.	





Although	 specific	 guidelines	 for	 variant	 interpretation	 in	 TIER1	




disease	 associations	 using	 a	 comprehensive	 and	 publicly	 available	
criteria	 using	 evidence	 including	 the	 number	 of	 reported	 patients	
with	variants	 in	 the	gene	and	supporting	experimental	data	 for	all	
rare	diseases.14	A	ClinGen	clinical	domain	working	group	for	throm-





RASopathies)	 have	 applied	 detailed	 scoring	 system	 using	 asso-
ciation's	strength	classified	as	definitive,	strong,	moderate,	 limited,	
disputed,	 or	 no	 evidence	 to	 systematically	 evaluate	 gene-	disease	
relationships.15,16	Because	of	the	urgent	need	in	diagnostic	genetic	
laboratories,	the	SSC-	GinTH	has	already	applied	a	simplified	scoring	





diagnostic	 laboratories.	 Further,	 we	 find	 that	 review	 of	 previous	
cases	while	 updating	 clinical	 validity	 of	 gene-	disease	 relationships	
can	 contribute	 to	 increased	diagnostic	 rates	 resulting	 in	 improved	
patient	care.
When	 implementing	 the	 BTPD	 gene	 list	 for	 diagnostics,	 good	
















sider	 the	 local	 laws	of	 the	country,	 the	 risks	of	discrimination,	 the	
policy	of	 the	genetic	 testing	 service,	 and	 the	age	of	 the	 individual	
being	tested.	Our	main	goal	was	to	deliver	a	curated	BTPD	disease-	
causing	gene	list	for	use	by	diagnostic	laboratories;	however,	as	ge-
netic	 testing	 becomes	 more	 common	 through	 biobanking	 studies	
and	direct-	to-	consumer	testing,	this	list	may	also	be	used	in	research	
studies	 and	 to	 aid	 appropriate	 feedback	 of	 genetic	 information	 to	
participants.
The	rapid	pace	of	gene	discovery	using	whole	exome	sequencing	
or	whole	 genome	 sequencing	 approaches	 also	 emphasizes	 a	 need	
for	data	 sharing.	Many	 recent	putative	discoveries	were	made	 for	
single	small	pedigrees,	sometimes	accompanied	by	limited	functional	
studies	and	no	mouse	model;	 therefore,	without	further	evidence,	
these	 genes	 are	 designated	 TIER2.	 These	 include	macrothrombo-
cytopenia	resulting	from	a	recessive	missense	variant	in	PRKACG,19 
macrothrombocytopenia	 from	dominant	 loss-	of-	function	variant	 in	
TPM4,20	 macrothrombocytopenia	 from	 a	 dominant	 missense	 vari-
ant in TRPM7,21	 a	 platelet	 function	 defect	 from	 recessive	 EPHB2 
variants,22	and	thrombocytopenia	from	a	recessive	PTPRJ	LoF	vari-
ants.23	Such	TIER2	genes	are	relevant	for	BPTD	diagnostics	but	still	




GinTH	now	provide	 a	well-	curated	 and	 evidence-	based	 catalog	of	
TIER1	gene-	disease	associations	that	can	be	used	for	diagnostic	ge-
netic	screening	of	BTPD	patients.
8  |     MEGY Et al.
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